Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review

Jianzheng Wang, Hongle Li, Hui Wang, Qingli Li, Xuanye Bai, Huifang Lv, Caiyun Nie, Beibei Chen, Weifeng Xu, Shuiping Tu, Xiaobing ChenFrontiers in Oncology 2022 · DOI

TL;DR

This case report introduces a novel combination therapy of anlotinib (a multi-target tyrosine kinase inhibitor) and celecoxib (a COX-2 inhibitor) for abdominal desmoid tumors. The treatment resulted in significant tumor reduction and complete pain relief in a patient, suggesting a promising new therapeutic avenue for this rare and challenging disease.

What Problem Does This Paper Address?

Desmoid tumors (DTs), also known as aggressive fibromatosis, are rare, locally invasive tumors characterized by fibroblast proliferation. While surgical resection is the primary treatment, recurrence rates are high. Existing treatments like endocrine therapy, radiotherapy, and chemotherapy have varying success rates, and targeted therapies have historically shown limited efficacy, often reserved as a last resort. There's a clear need for more effective and less toxic treatment options, especially for aggressive or recurrent cases, and a lack of established treatment protocols for abdominal desmoid tumors. This paper addresses the challenge of finding a successful treatment for a patient with an aggressive abdominal desmoid tumor that had not responded well to previous interventions.

Methods

This paper presents a case report of a 50-year-old woman with an abdominal desmoid tumor. The treatment involved a combination of anlotinib and celecoxib. Anlotinib was administered orally at 10mg twice daily on days 1-14 of each 21-day cycle, and celecoxib was given at 0.1g twice daily. The treatment regimen was followed for 22 cycles. The study also includes a literature review to contextualize the findings within existing research on desmoid tumor treatments. Diagnostic methods included color Doppler ultrasound, enhanced CT scans, exploratory laparotomy with biopsy, and immunohistochemical staining. Tumor response was assessed using imaging (CT scans) and patient-reported pain scores (NRS).

Datasets

Not discussed in the paper. This is a case report and literature review, not a study involving large datasets for training or evaluation.

Key Insights and Ideas

  • Synergistic Potential of Anlotinib and NSAIDs: The most significant insight is the apparent synergistic effect of combining anlotinib (a tyrosine kinase inhibitor targeting angiogenesis and tumor growth) with celecoxib (a COX-2 inhibitor, a type of NSAID). This combination appears to be more effective than either agent alone for desmoid tumors.
  • Pain Management Breakthrough: The complete resolution of pain symptoms, alongside tumor reduction, highlights the potential of this combination therapy not just for tumor control but also for improving patient quality of life, a critical aspect in managing desmoid tumors.
  • Targeted Therapy Evolution: The paper underscores the evolving landscape of targeted therapies for desmoid tumors, moving beyond older agents to newer drugs like anlotinib, which show promise.
  • Abdominal DTs as a Specific Challenge: The focus on an abdominal desmoid tumor highlights a specific anatomical location that can present unique challenges in treatment and management.

Key Results

  • Tumor Response: The patient achieved a partial response (PR) in tumor size, as evidenced by CT scans showing significant reduction.
  • Pain Relief: The patient's pain symptoms completely disappeared, with the Numerical Rating Scale (NRS) score dropping to 0.
  • Progression-Free Survival (PFS): The patient's tumor was significantly reduced, and the progression-free survival exceeded 18 months at the time of reporting.
  • Toxicity: The treatment was associated with mild toxicity.
  • Treatment Duration: The patient received 22 cycles of the combined anlotinib and celecoxib regimen.

Limitations and Future Work

  • Single Case Report: The primary limitation is that these findings are based on a single patient. This limits the generalizability of the results.
  • Need for Larger Studies: The authors emphasize the need for larger, prospective studies to confirm the efficacy and safety of this combination therapy for desmoid tumors.
  • Optimal Dosing: While a specific dosage was used, the optimal combination dose for anlotinib and NSAIDs requires further exploration.
  • Long-Term Outcomes: The long-term efficacy and safety profile of this combination therapy remain to be fully determined.
  • Mechanism Exploration: Further research into the precise mechanisms by which anlotinib and NSAIDs interact to treat desmoid tumors is warranted.
  • Quality of Life Assessment: While pain was addressed, future studies should incorporate comprehensive health-related quality of life (HRQOL) assessments.

Summary updated

Abstract

Desmoid tumor is a rare disease, which is histologically characterized by local invasion, monoclonality, and fibroblast proliferation; and clinically characterized by a variable and often unpredictable course. The treatment of desmoid tumor is mainly surgical resection, but the recurrence rate is high. In recent years, a variety of treatment methods, including endocrine therapy, surgery, radiotherapy, chemotherapy, non-steroidal anti-inflammatory drugs, targeted drugs, interferon and more, have been used and achieved certain curative effects. In addition, in view of the inertia characteristics of desmoid tumor, observation is also a first-line scheme recommended by multiple guidelines. In the past, the research progress of targeted therapy for desmoid tumor is relatively slow and the curative effect is limited. Thus, targeted therapy is usually used as a remedial treatment after the failure of other conventional treatment methods. However, in recent years, with the rapid progress in the basic research of targeted therapy, some new targeted drugs are increasingly used for the clinical treatment of desmoid tumor and have achieved good results. Herein, we described a patient with aggressive fibromatosis in the abdominal cavity. Following a combined treatment using anlotinib and celecoxib, the patient achieved a partial response with mild toxicity. Simultaneously, the patient's pain symptoms completely disappeared. This case indicates that the combination of anlotinib and NSAIDs could be an effective treatment for desmoid tumor.
BibTeX
@inproceedings{wang2022combination,
  author = {Jianzheng Wang and Hongle Li and Hui Wang and Qingli Li and Xuanye Bai and Huifang Lv and Caiyun Nie and Beibei Chen and Weifeng Xu and Shuiping Tu and Xiaobing Chen},
  title = {{Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2021.830672},
}
Figure